3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes

Glycemic Control Targets & Management

Once GDM is diagnosed, the patient initiates daily blood glucose self-monitoring and lifestyle modifications. Standard capillary fingerstick monitoring is performed four times daily: upon waking (fasting) and 1 or 2 hours after the start of each major meal (breakfast, lunch, and dinner).

Target Blood Glucose Thresholds (ACOG & ADA)

• Fasting: <95 mg/dL (5.3 mmol/L)
• 1-Hour Postprandial: <140 mg/dL (7.8 mmol/L)
• 2-Hour Postprandial: <120 mg/dL (6.7 mmol/L)
• Mean 24-hour Glucose: ~100 mg/dL; target HbA1c in pregnancy is <6.0% (if attainable without severe hypoglycemia).

Medical Nutrition Therapy (MNT)

Medical Nutrition Therapy tailored by a registered dietitian is the foundation of management for all patients with GDM (A1GDM):

• Caloric Allocation: Based on pre-pregnancy BMI:
  • Normal weight (BMI 18.5–24.9): 30 kcal/kg/day
  • Overweight (BMI 25.0–29.9): 22–25 kcal/kg/day
  • Obese (BMI ≥30): 22–25 kcal/kg/day (a moderate caloric reduction of ~30% reduces hyperglycemia without inducing maternal ketonemia).
  • Minimum carbohydrate intake: ≥175 g/day to prevent maternal ketosis, which is potentially neurotoxic to the developing fetal brain.
• Macronutrient Composition:
  • Carbohydrates: 35% to 45% of total daily calories, emphasizing complex, low-glycemic-index carbohydrates with abundant dietary fiber (≥28 g/day).
  • Protein: 20% to 25% of daily calories.
  • Fats: 30% to 40% of daily calories, predominantly monounsaturated and polyunsaturated fatty acids.
• Meal Distribution: Three moderate meals and two to three snacks daily. The morning breakfast meal should contain the lowest carbohydrate proportion (e.g., 15–30 grams) because morning cortisol and hPL levels peak, causing pronounced morning insulin resistance.
• Physical Activity: Moderate aerobic exercise for 30 minutes, 5 days per week, or 10- to 15-minute brisk walks after each meal significantly improves skeletal muscle glucose uptake and blunts postprandial glucose surges.

Pharmacologic Management (A2GDM)

Pharmacotherapy is indicated when Medical Nutrition Therapy fails to maintain euglycemia—specifically when ≥10% to 20% of capillary blood glucose values exceed target thresholds within a 1- to 2-week monitoring interval, or when ultrasound demonstrates accelerated fetal abdominal circumference (>75th percentile).

1. Insulin (First-Line Gold Standard)

Insulin is the primary, preferred pharmacologic therapy endorsed by ACOG, ADA, and SMFM because it does not cross the placenta in significant amounts and provides precise dose titration.

• Regimens: Typically combines intermediate- or long-acting basal insulin with rapid-acting prandial analogues.
  • Basal: NPH insulin (historically preferred; intermediate duration) or long-acting analogues (insulin detemir or insulin glargine, which provide steady, peakless coverage).
  • Prandial: Rapid-acting insulin analogues (lispro or aspart) injected 5 to 15 minutes before meals. They are superior to regular human insulin due to faster onset, shorter duration, and lower risk of delayed hypoglycemia.
• Total Daily Dose (TDD) Calculation: Starting dose ranges from 0.7 to 1.0 units/kg of current pregnancy weight/day depending on gestational age (0.7 U/kg in 1st trimester; 0.8 U/kg at 18–26w; 0.9 U/kg at 26–36w; 1.0 U/kg at 36w to term). A standard split divides TDD into two-thirds in the morning (2/3 intermediate, 1/3 rapid) and one-third in the evening (split between rapid before dinner and intermediate at bedtime), or basal-bolus dosing (50% basal, 50% prandial divided among meals).

2. Metformin

• Mechanism & Placental Transfer: Biguanide that decreases hepatic gluconeogenesis and increases peripheral glucose utilization. Metformin readily crosses the placenta, achieving umbilical cord blood concentrations equal to or higher than maternal levels.
• Clinical Status: Acceptable second-line agent when a patient declines insulin, cannot safely store or inject insulin, or cannot afford it. Studies show higher rates of preterm birth and smaller infant size at birth, but lower maternal gestational weight gain and preeclampsia rates compared to insulin. Long-term pediatric metabolic outcomes remain under active investigation.

3. Glyburide

• Mechanism & Placental Transfer: Second-generation sulfonylurea that stimulates pancreatic beta-cell insulin secretion. Crosses the placenta in significant concentrations.
• Clinical Status: Associated with higher rates of macrosomia, neonatal hypoglycemia, and admission to the neonatal intensive care unit compared to both insulin and metformin. Consequently, glyburide is not recommended as a first-line agent.

---

Fetal Surveillance and Delivery Timing in GDM

• A1GDM (Diet-Controlled): Routine antepartum fetal surveillance (nonstress tests [NST] or biophysical profiles [BPP]) is not indicated if blood glucose levels remain well-controlled, unless other obstetric risk factors (e.g., chronic hypertension, advanced maternal age, suspected fetal growth restriction) supervene. Delivery is recommended between 39 0/7 and 40 6/7 weeks gestation; expectant management beyond 41 weeks is avoided.
• A2GDM (Medication-Controlled): Antenatal fetal surveillance (twice-weekly NSTs or modified BPP) is initiated at 32 0/7 to 36 0/7 weeks gestation. Serial ultrasound biometry is performed every 3 to 4 weeks starting at 28 to 32 weeks to evaluate fetal abdominal circumference and estimated fetal weight (EFW). Planned delivery is recommended between 39 0/7 and 39 6/7 weeks gestation (or earlier, between 37 0/7 and 38 6/7 weeks, if glycemic control is persistently subtherapeutic or maternal/fetal vascular complications arise).
• Cesarean Delivery for Suspected Macrosomia: When estimated fetal weight exceeds 4,500 grams in a diabetic pregnancy, the clinician must counsel the patient regarding the markedly elevated risk of shoulder dystocia, permanent brachial plexus injury, and maternal perineal trauma, offering planned elective cesarean delivery.

---